Steven Cohen's SUPN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.32 M shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $68.16 M, representing 0.09% of the portfolio. First purchased in 2016-Q1, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in SUPN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 1.25 M shares. Largest reduction occurred in Q1 2026, reducing 946,245 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Supernus Pharmaceuticals (SUPN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Supernus Pharmaceuticals (SUPN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -946,245 | Reduce 41.78% | 1.32 M | $51.69 |
| Q4 2025 | +503,316 | Add 28.57% | 2.26 M | $49.70 |
| Q3 2025 | +1.25 M | Add 246.89% | 1.76 M | $47.79 |
| Q2 2025 | +188,887 | Add 59.23% | 507,790 | $31.52 |
| Q1 2025 | +292,075 | Add 1088.69% | 318,903 | $32.75 |
| Q4 2024 | +26,828 | New Buy | 26,828 | $36.16 |
| Q3 2024 | -136,342 | Sold Out | 0 | $0.00 |
| Q2 2024 | +8,521 | Add 6.67% | 136,342 | $26.75 |
| Q1 2024 | +127,821 | New Buy | 127,821 | $34.11 |
| Q2 2023 | -755 | Sold Out | 0 | $0.00 |
| Q1 2023 | +755 | New Buy | 755 | $36.23 |
| Q2 2020 | -346,666 | Sold Out | 0 | $0.00 |
| Q1 2020 | +346,666 | New Buy | 346,666 | $17.99 |
| Q1 2017 | -1,900 | Sold Out | 0 | $0.00 |
| Q4 2016 | +1,900 | New Buy | 1,900 | $25.26 |
| Q3 2016 | -35,600 | Sold Out | 0 | $0.00 |
| Q2 2016 | -909,146 | Reduce 96.23% | 35,600 | $20.37 |
| Q1 2016 | +944,746 | New Buy | 944,746 | $15.25 |
Steven Cohen's Supernus Pharmaceuticals Investment FAQs
Steven Cohen first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q1 2016, acquiring 944,746 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Supernus Pharmaceuticals, Inc. (SUPN) for 18 quarters since Q1 2016.
Steven Cohen's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q3 2025, adding 1,761,484 shares worth $84.18 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,318,555 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $68.16 M.
As of the Q1 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.09% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 2,264,800 shares, as reported at the end of Q4 2025.